{"acquisitions":[],"changes":[],"country":"FR","description":"ReST Therapeutics develops FENM, a small molecule that modulates NMDA-receptor activity to treat central nervous system disorders such as PTSD and Alzheimer's. It targets patients with neurodegenerative and stress-related conditions. Its NMDA-subtype modulation aims to halt disease progression, not just relieve symptoms.","domain":"rest-therapeutics.com","employees":null,"founded":2020,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":43.6108,"lng":3.8767,"location":"Montpellier, France","multiples":[],"name":"Rest Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":2700000,"connectionsAmong":[],"currency":"EUR","date":"2023-07-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"rest-therapeutics-com-2023-07-01-grant","source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"rest-therapeutics-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"rest-therapeutics.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://rest-therapeutics.com"},{"fact":"description","publisher":"rest-therapeutics.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://rest-therapeutics.com"}],"stage":null,"stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":5000000,"traction":[],"updatedAt":"2026-05-08","valuations":[]}